CCL2 and Alzheimer disease: In the context of AD, inhibition of the TLR4/MyD88 pathway by Irisins could reduce HMGB1 and MCP-1 expression, effectively mitigating inflammation-induced neuronal damage and slowing disease progression (Ruganzu et al., 2022).